Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Quiet Board

<< Previous

Bullboard Posts

Next >>

Comment by Stocker46on Mar 15, 2021 11:10am

147 Views

Post# 32798436

RE:RE:RE:RE:RE:Quiet Board

NEWS FLASH stockfy - the idea of investing in the stock market is to buy low & sell high.
Already stated I believe the SP could go significantly higher. Unfortunately, this Trulance fiasco is a big deal. It will not only wipe out all or a major portion of 2020 earnings, but will also affect 2021 earnings. Problem is we have no idea by how much.

Hopefully, their upcoming conference call will provide some clarity.
If it doesn't, then I'll pass for now.

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter